Compare Abbott Laboratories (ABT) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Verisign, Inc. — how do they compare? Abbott Laboratories trades at $95.34 (market cap $166.94B), while Verisign, Inc. trades at $267.41 (market cap $24.28B). The key difference: Abbott Laboratories is far larger — about 6.9× Verisign, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | VRSN | |
|---|---|---|
Market Cap | $166.94B | $24.28B |
Sector | Health | Technology |
52-Week High | $136.62 | $310.00 |
52-Week Low | $82.57 | $211.49 |
Enterprise Value | $193.69B | $25.52B |
Dividend Yield | 2.63% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VeriSign (VRSN) trades at $266.78, up 4.04% on the day, with a bearish technical signal and mixed earnings history including a Q1 2026 beat. The stock shows strong fundamentals with 49.96% net income margin and $825.7M net income for 2025, though negative shareholder equity remains a concern. Recent news highlights AI-driven domain growth and upcoming Q2 2026 earnings.
Outlook is cautiously optimistic with 57% analyst buy ratings and a $327.67 consensus target offering 23% upside. Key risks include contract renewals, AI disruption potential, and high debt levels. Revenue growth stability and margin strength support investment case, but technical resistance near $266 requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
